Last reviewed · How we verify
NCT06242405
Effect of Different Frequencies of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
NA trial testing umbilical cord-mesenchymal stem cells in End-Stage Liver DIsease in 92 participants. Completed in 30 December 2025.
30 December 2025
Quick facts
| Lead sponsor | General Hospital of Shenyang Military Region |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 92 |
| Start date | 5 March 2024 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- umbilical cord-mesenchymal stem cells — full drug profile →
Conditions studied
- End-Stage Liver DIsease — all drugs for End-Stage Liver DIsease →
Sponsor
General Hospital of Shenyang Military Region
Who can join
Adults 18 to 80, any sex, with End-Stage Liver DIsease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury. Randomized controlled trials have confirmed the efficacy of single infusion of stem cells in treating ESLD. It seems that the multiple infusion is better than single infusion.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials.
Huang WC, Li YC, Chen PX, Ma KS, et al · · 2025 · cited 14× · PMID 39762946 · DOI 10.1186/s13287-024-04127-y -
From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy.
Bozorgi V, Babaahmadi M, Salehi M, Vafaeimanesh J, et al · · 2025 · cited 4× · PMID 40764597 · DOI 10.1186/s13287-025-04535-8 -
Stem cell-based therapeutic strategies for liver aging.
Niu H, Wang YN, Ding Y, Lin YQ, et al · · 2025 · cited 1× · PMID 40620500 · DOI 10.1016/j.livres.2025.04.003 -
Application of stem cells in the precise diagnosis and treatment of liver diseases.
Wang YX, Ren YN, Zhang SS, Sun S, et al · · 2025 · PMID 41479645 · DOI 10.3748/wjg.v31.i46.114415
Verify or expand the search:
- PubMed search for NCT06242405
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of umbilical cord-mesenchymal stem cells
Trials testing the same drug.
- NCT06167473 — Effect of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD · NA · completed
Other General Hospital of Shenyang Military Region trials
Trials by the same sponsor.
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07462546 — Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS) · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT07412249 — Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06242405 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by General Hospital of Shenyang Military Region
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06242405.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing